Welcome to our dedicated page for Xeris Biopharma Holdings SEC filings (Ticker: XERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a commercial-stage biopharmaceutical issuer, Xeris uses these filings to report financial results, describe product performance for Recorlev, Gvoke, and Keveyis, and update investors on developments in its pipeline and technology platforms, including XP-8121 and the XeriSol and XeriJect technologies.
Key documents for XERS include current reports on Form 8-K, which Xeris uses to furnish press releases detailing quarterly and year-to-date results, revenue by product, cost of goods sold, research and development spending, selling, general and administrative expenses, and non-GAAP measures such as Adjusted EBITDA. These filings also summarize business highlights, such as changes in demand across the company’s commercial products, updates to revenue guidance, and commentary on investments in Recorlev commercialization and pipeline advancement.
In addition to 8-Ks, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q for a more comprehensive view of Xeris’ business, including risk factors, segment information, and detailed financial statements. Proxy statements and other filings can provide information on governance and compensation, while ownership and insider transaction reports on forms such as Form 4 can show equity awards and trading activity by directors and officers.
On Stock Titan, these SEC filings are supplemented with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand revenue trends, product performance, and key disclosures without reading every page. Real-time updates from EDGAR help ensure that new XERS filings, including 10-Ks, 10-Qs, 8-Ks, and Form 4 reports, are available as they are posted, giving investors a structured way to review Xeris’ regulatory history and ongoing reporting.
The Vanguard Group has filed an amended Schedule 13G reporting beneficial ownership of Xeris Biopharma Holdings Inc common stock. Vanguard reports beneficial ownership of 11,186,677 shares, representing 6.74% of the outstanding common stock as of the triggering date.
Vanguard reports no sole voting or dispositive power, with shared voting power over 1,339,227 shares and shared dispositive power over 11,186,677 shares. The filing explains that Vanguard’s clients, including registered investment companies and other managed accounts, have the right to receive dividends and sale proceeds, and that no single client holds more than 5% of the class. Vanguard states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Xeris Biopharma. The filing also notes an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries may report beneficial ownership on a disaggregated basis.
Xeris Biopharma Holdings, Inc. officer Kevin McCulloch reported selling 15,000 shares of common stock at $8.00 per share on January 8, 2026. The sale was executed under a Rule 10b5-1 trading plan adopted by the reporting person. After this transaction, he beneficially owned 1,685,426 shares of common stock directly and 25,000 shares indirectly through his spouse. He serves as President and Chief Operating Officer of the company.
An insider has filed a Form 144 indicating an intention to sell 60,000 shares of common stock of issuer XERS through Morgan Stanley Smith Barney LLC on or around 01/08/2026, with the shares listed on the NASDAQ. The filing cites an aggregate market value of $432,600.00 for this planned sale.
The shares to be sold were acquired as restricted stock units from the issuer on 01/31/2021. As context, the filing notes that there were 165,924,289 shares of this class outstanding.
Xeris Biopharma Holdings, Inc. filed a current report to disclose that it has issued a press release with certain preliminary financial results for the fourth quarter and full year ended December 31, 2025. The press release is provided as Exhibit 99.1 and offers an early view of the company’s recent performance before final audited figures are available. The company states that this financial information, including Exhibit 99.1, is being furnished rather than filed, which affects how it is treated under securities laws.
Xeris Biopharma Holdings director reports preset stock sale. An Xeris Biopharma Holdings, Inc. director reported selling 15,000 shares of common stock on 12/12/2025, identified with transaction code "S." The shares were sold at a weighted average price of $7.0943 per share.
The disclosure states the transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. After this sale, the director beneficially owns 142,500 shares of Xeris Biopharma common stock directly.
Xeris Biopharma Holdings (XERS) filed a Form 4 showing option exercises and a share sale by its Chief Executive Officer and Director. On 11/13/2025, the reporting person exercised stock options to acquire 8,970 shares of common stock at an exercise price of $1.55 per share and sold 23,242 shares of common stock at a weighted average price of $7.4607, all under a pre-arranged Rule 10b5-1 trading plan. After these transactions on that date, the reporting person held 2,643,153 shares of common stock directly. On 11/14/2025, the reporting person exercised additional stock options for 87,100 shares at $1.55 per share, increasing the directly held common stock position to 2,730,253 shares. Following these transactions, the person also held 64,265 stock options with an exercise price of $1.55 per share expiring on 02/03/2027.
Xeris Biopharma (XERS) reported an insider transaction by an officer. On 11/11/2025, the reporting person sold 16,667 shares of common stock at a weighted average price of $7.3976, executed under a Rule 10b5-1 trading plan.
Following the sale, the filer directly beneficially owned 1,336,843 shares. The sale price reflects multiple trades between $7.290 and $7.750. The reporting person is the company’s Chief Legal Officer and Corporate Secretary.
Xeris Biopharma reported stronger Q3 results. Total revenue reached $74.380 million (up 37.1% year over year), led by Recorlev $36.975 million, Gvoke $25.151 million, and Keveyis $11.937 million. Operating income was $6.731 million versus a loss a year ago, and net income was $621 thousand.
For the first nine months, revenue was $206.038 million with a net loss of $10.527 million. Cost discipline and mix improved gross costs: cost of goods sold fell to 14.8% of product revenue in Q3 from 25.7% a year earlier, aided by fewer inventory write-offs.
Cash and cash equivalents were $91.598 million and total cash, cash equivalents and restricted cash were $95.619 million. Net debt stood at $219.469 million (including $33.6 million of 2028 convertible notes and $188.045 million of 2029 loans). Stockholders’ equity (deficit) improved to $(0.861) million from $(29.615) million at year-end. Management believes cash resources are sufficient for at least the next 12 months, while noting ongoing net losses and market risks.
Xeris Biopharma Holdings, Inc. furnished an 8-K announcing a press release with results of operations and business highlights for the three and nine months ended September 30, 2025. The press release is included as Exhibit 99.1.
The company states the information in Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference except as specifically set forth.
Xeris Biopharma Holdings insider Kevin McCulloch, listed as President and Chief Operating Officer, reported a transaction dated 10/02/2025. The filing shows 733 shares of common stock were disposed of at $8.31; the explanation states these shares were withheld by the issuer to satisfy tax and withholding obligations in connection with the net settlement of restricted stock units that vested on that date. After the reported transaction, Mr. McCulloch beneficially owns 1,700,426 shares directly. The report also lists 25,000 shares held indirectly by his spouse, with the reporting person disclaiming beneficial ownership except for pecuniary interest.